275 related articles for article (PubMed ID: 25522796)
21. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
[TBL] [Abstract][Full Text] [Related]
22. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
23. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
24. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
Meintjes G; Stek C; Blumenthal L; Thienemann F; Schutz C; Buyze J; Ravinetto R; van Loen H; Nair A; Jackson A; Colebunders R; Maartens G; Wilkinson RJ; Lynen L;
N Engl J Med; 2018 Nov; 379(20):1915-1925. PubMed ID: 30428290
[TBL] [Abstract][Full Text] [Related]
25. Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study.
Melkamu MW; Gebeyehu MT; Afenigus AD; Hibstie YT; Temesgen B; Petrucka P; Alebel A
BMC Infect Dis; 2020 Jan; 20(1):50. PubMed ID: 31948393
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
27. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
[TBL] [Abstract][Full Text] [Related]
28. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
[TBL] [Abstract][Full Text] [Related]
29. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town.
Kaplan R; Hermans S; Caldwell J; Jennings K; Bekker LG; Wood R
BMC Infect Dis; 2018 Jul; 18(1):356. PubMed ID: 30064368
[TBL] [Abstract][Full Text] [Related]
30. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
McGrath N; Lessells RJ; Newell ML
HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
[TBL] [Abstract][Full Text] [Related]
31. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
[TBL] [Abstract][Full Text] [Related]
32. Determinant factors for the occurrence of tuberculosis after initiation of antiretroviral treatment among adult patients living with HIV at Dessie Referral Hospital, South Wollo, Northeast Ethiopia, 2020. A case-control study.
Abdu M; Ali Y; Anteneh S; Yesuf M; Birhanu A; Mohamed S; Hussien A
PLoS One; 2021; 16(3):e0248490. PubMed ID: 33724992
[TBL] [Abstract][Full Text] [Related]
33. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting.
Houben RM; Glynn JR; Mboma S; Mzemba T; Mwaungulu NJ; Mwaungulu L; Mwenibabu M; Mpunga J; French N; Crampin AC
AIDS; 2012 Nov; 26(17):2233-9. PubMed ID: 22951633
[TBL] [Abstract][Full Text] [Related]
34. Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinic-based observational cohort study in four African countries.
Esber AL; Coakley P; Ake JA; Bahemana E; Adamu Y; Kiweewa F; Maswai J; Owuoth J; Robb ML; Polyak CS; Crowell TA;
J Int AIDS Soc; 2020 Feb; 23(2):e25446. PubMed ID: 32064776
[TBL] [Abstract][Full Text] [Related]
35. CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.
Collins SE; Jean Juste MA; Koenig SP; Secours R; Ocheretina O; Bernard D; Riviere C; Calnan M; Dunning A; Hurtado Rúa SM; Johnson WD; Pape JW; Fitzgerald DW; Severe P
Int J Tuberc Lung Dis; 2015 Jan; 19(1):50-7. PubMed ID: 25519790
[TBL] [Abstract][Full Text] [Related]
36. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.
Lawn SD; Török ME; Wood R
Curr Opin Infect Dis; 2011 Feb; 24(1):34-42. PubMed ID: 21150593
[TBL] [Abstract][Full Text] [Related]
37. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
[TBL] [Abstract][Full Text] [Related]
38. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
[TBL] [Abstract][Full Text] [Related]
39. Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.
Bohlius J; Valeri F; Maskew M; Prozesky H; Garone D; Sengayi M; Fox MP; Davies MA; Egger M
Int J Cancer; 2014 Dec; 135(11):2644-52. PubMed ID: 24729433
[TBL] [Abstract][Full Text] [Related]
40. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
